PAVmed(PAVM) - 2024 Q1 - Quarterly Results

Exhibit 99.1 PAVmed Provides Business Update and First Quarter 2024 Financial Results Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting date ● Yesterday, Lucid reported that 1Q24 EsoGuard revenue was $1.0 million, which was flat compared to 4Q23 and represents a 124 percent increase from 1Q23. ● Strengthened balance sheet by Lucid's completion of a$29.8 million Series B Preferred Stock Offering. Veris Health completes MOU with The Ohio State's James Cancer Hospital Co ...